Iod-131-Ganzkörperszintigraphie beim differenzierten Schilddrüsenkarzinom

Frederik A. Verburg; Frank Grünwald; Michael Lassmann; Heribert Hänscheid; Markus Luster; Markus Dietlein

doi:10.1055/s-0038-1649554

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 2018; 57(04): 124-136
DOI: 10.1055/s-0038-1649554

DGN-Handlungsempfehlung (S1-Leitlinie)

Georg Thieme Verlag

Iod-131-Ganzkörperszintigraphie beim differenzierten Schilddrüsenkarzinom

Stand: 7/2017 – AWMF-Registernummer: 031–013Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma

Frederik A. Verburg

¹Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Nuklearmedizin

,

Frank Grünwald

²Klinik und Poliklinik für Nuklearmedizin der Universität Frankfurt

,

Michael Lassmann

³Klinik und Poliklinik für Nuklearmedizin der Universität Würzburg

,

Heribert Hänscheid

³Klinik und Poliklinik für Nuklearmedizin der Universität Würzburg

,

Markus Luster

¹Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Nuklearmedizin

,

Markus Dietlein

⁴Klinik und Poliklinik für Nuklearmedizin des Universitätsklinikums Köln

› Author Affiliations

Abstract

Zusammenfassung

Die Version 4 der Verfahrensanweisung für die Iod-131-Ganzkörperszintigraphie beim differenzierten Schilddrüsenkarzinom ist ein Update der Version 3, die im Jahr 2007 durch die Deutsche Gesellschaft für Nuklearmedizin (DGN) und die Deutsche Gesellschaft für Medizinische Physik (DGMP) publiziert wurde. Diese Verfahrensanweisung beschreibt mit primärer Zielsetzung die fachgerechte Durchführung der Ganzkörperszintigraphie nach Applikation einer diagnostischen bzw. therapeutischen I-131-Aktivität. Die aktualisierten Indikationen zur I-131-Ganzkörperszintigraphie werden in der Verfahrensanweisung aufgelistet. Neue Erkenntnisse bezüglich der Beziehung zwischen verabreichter Aktivität und Bildqualität wurden in der aktualisierten Verfahrungsanweisung berücksichtigt. Die Verfahrensanweisung wurde von einer repräsentativen Expertengruppe im Konsensverfahren verabschiedet. Sie entspricht damit einer Verfahrensanweisung der ersten Stufe (S1) nach den Kriterien der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Zusätzlich wurden Indikationsstellung, Zeitpunkt und Aktivitätswahl für die diagnostische Ganzkörperszintigraphie im erweiterten Kollegenkreis am 30. November 2012, am 19. April 2013 und am 23. April 2015 bei Tagungen der Arbeitsgemeinschaft Schilddrüse der Deutschen Gesellschaft für Nuklearmedizin ausführlich diskutiert.

Summary

Version 4 of the procedural guideline for Iodine-131 whole-body scintigraphy (WBS) in differentiated thyroid carcinoma is an update of the version 3, which was published by the “Deutsche Gesellschaft für Nuklearmedizin” (DGN) and the “Deutsche Gesellschaft für Medizinische Physik” (DGMP) in 2007. This procedural guideline advises on how to best perform I-131 whole body scintigraphy after I-131 therapy or after application of a diagnostic I-131 activity. The updated relevant medical indications for I-131 whole body scintigraphy are given in this procedural guideline. Novel insights on the relationship bet¬ween activity and image quality were incorporated in the updated recommendations. A representative expert group has discussed and reached consensus on the procedural guideline; the development of this procedural guideline therefore fulfils the criteria for level S1 (first step) within the classification of the German Workgroup of Scientific Medical Societies (“Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften”; AWMF). Additionally, indications for WBS, timing and activity for WBS were discussed by the working group “Thyroid” of the DGN on November 30th 2012, April 19th, 2013 and on April 23rd, 2015.

Schlüsselwörter

Differenziertes Schilddrüsenkarzinom - Verfahrensanweisung - I-131 - Ganzkörperszintigraphie

Keywords

Differentiated thyroid carcinoma - procedural guideline - I-131 - whole-body scintigraphy

Full Text

References

Literatur
1 DIN 6855–2 Konstanzprüfung von Einkristall- Gammakameras zur planaren Szintigraphie und zur Einzelphotonen-Emissions-Tomographie mit Hilfe rotierender Messköpfe (Januar 2005). 2005
2 Bachelot A, Leboulleux S, Baudin E, Hartl DM, Caillou B, Travagli JP, Schlumberger M. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf) 2005; 62: 376-379.
3 Bundesministerium für Umwelt NuR. Strahlenschutz in der Medizin. Richtlinie zur Verordnung über den Schutz vor Schäden durch ionisierende Strahlen. 11–7–2014.
4 Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J Clin Endocrinol Metab 2000; 85: 175-178.
5 Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 2001; 86: 5627-5632.
6 Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003; 139: 346-351.
7 Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, Lee DS, Lee MC, Cho BY. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002; 57: 215-221.
8 Cooper DS, Doherty GM, Haugen BR. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
9 de Meer SG, Vriens MR, Zelissen PM, Borel RI, de Keizer B. The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer. J Nucl Med 2011; 52: 56-59.
10 de Pont C, Halders S, Bucerius J, Mottaghy F, Brans B. (124)I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy (131)I SPECT/CT. Eur J Nucl Med Mol Imaging. 2013
11 Dewaraja YK, Ljungberg M, Green AJ. et al. MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med 2013; 54: 2182-2188.
12 Diessl S, Verburg F, Biko J, Schryen B, Reiners C, Buck A, Hanscheid H. Improved follow-up of patients with differentiated thyroid carcinoma. The quantitative detection limit of 131I uptake in diagnostic scans. Nuklearmedizin 2013; 52.
13 Dietlein M, Eschner W, Grunwald F, Lassmann M, Verburg FA, Luster M. Verfahrensanweisung zur Radioiodtherapie beim differenzierten Schilddrüsenkarzinom (Version 4). Nuklearmedizin. 2015
14 Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468-1472.
15 Feine U, Lietzenmayer R, Hanke JP, Wohrle H, Muller-Schauenburg W. [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. Nuklearmedizin 1995; 34: 127-134.
16 Freudenberg LS, Frilling A, Kuhl H, Muller SP, Jentzen W, Bockisch A, Antoch G. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 2007; 17: 3139-3147.
17 Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, Bockisch A. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 2007; 121-128.
18 Gerard SK, Cavalieri RR. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med 2002; 27: 1-8.
19 Geworski L, Lottes G, Reiners C, Schober O. Empfehlungen zur Qualitätskontrolle in der Nuklearmedizin. Stuttgart: Schattauer; 2009
20 Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck 2012; 34: 626-631.
21 Giovanella L, Treglia G, Ceriani L, Verburg F. Detectable thyroglobulin with negative imaging in differentiated thyroid cancer patients. What to do with negative anatomical imaging and radioiodine scan? Nuklearmedizin 2014; 53: 1-10.
22 Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, Verburg FA. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab 2014; 99: 440-447.
23 Giovanella L, Trimboli P, Verburg FA, Treglia G, Piccardo A, Foppiani L, Ceriani L. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive (18)F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2013; 40: 874-880.
24 Gotthardt M, Stubinger M, Pansegrau J, Buchwald B, Goecke J, Pfestroff A, Corstens FH, Behr TM. Decrease of (99m)Tc-uptake in autonomous thyroid tissue in Germany since the 1970s. Clinical implications for radioiodine therapy. Nuklearmedizin 2006; 45: 122-125.
25 Hanscheid H, Lassmann M, Buck AK, Reiners C, Verburg FA. The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma. Phys Med Biol 2014; 59: 2353-2368.
26 Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001; 42: 1464-1469.
27 Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic (131)I and (123)I. Eur J Nucl Med Mol Imaging 2002; 29: 783-788.
28 Hung BT, Huang SH, Huang YE, Wang PW. Appropriate time for post-therapeutic I-131 whole body scan. Clin Nucl Med 2009; 34: 339-342.
29 Jentzen W, Freudenberg L, Eising E, Sonnenschein WJ, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2008; 49: 1017-1023.
30 Kelders A, Kennes LN, Krohn T, Behrendt FF, Mottaghy FM, Verburg FA. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions. Nucl Med Commun 2014; 35: 176-181.
31 Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 1440-1445.
32 Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu JS, Gong G, Hong SJ, Shong YK. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008; 93: 4683-4689.
33 Klubo-Gwiezdzinska J, Van Nostrand D, Atkins F, Burman K, Jonklaas J, Mete M, Wartofsky L. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab 2011; 96: 3217-3225.
34 Kramer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Lerch H, Gerss J, Frankewitsch T, Schober O, Riemann B. Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MSDS trial. Eur J Endocrinol 2010; 163: 637-644.
35 Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002; 37: 169-174.
36 Lassmann M, Haenscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM dosimetry committee series on standard operational procedures for pretherapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008; 35: 1405-1412.
37 Lassmann M, Luster M, Hanscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004; 45: 619-625.
38 Lee JW, Lee SM, Koh GP, Lee DH. The comparison of (131)I whole-body scans on the third and tenth day after (131)I therapy in patients with well-differentiated thyroid cancer: preliminary report. Ann Nucl Med 2011; 25: 439-446.
39 Loffler M, Weckesser M, Franzius C, Kies P, Schober O. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin 2003; 42: 240-243.
40 Lundh C, Lindencrona U, Postgard P, Carlsson T, Nilsson M, Forssell-Aronsson E. Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells. J Nucl Med 2009; 50: 1161-1167.
41 Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1941-1959.
42 Mallick U, Harmer C, Yap B. et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366: 1674-1685.
43 Mazzaferri EL, Robbins RJ, Braverman LE. Authors’ response: a consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 4508-4509.
44 Mustafa M, Kuwert T, Weber K, Knesewitsch P, Negele T, Haug A, Linke R, Bartenstein P, Schmidt D. Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. Eur J Nucl Med Mol Imaging 2010; 37: 1462-1466.
45 Nemec J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979; 20: 92-97.
46 Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine wholebody scan may be avoided in thyroid cancer patients who have undetectable stimulated serum tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87: 1499-1501.
47 Pacini F, Mariotti S, Formica N, Elisei R, Anelli S, Capotorti E, Pinchera A. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol (Copenh) 1988; 119: 373-380.
48 Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
49 Phan TT, van Tol KM, Links TP, Piers DA, de Vries EG, Dullaart RP, Jager PL. Diagnostic I-131 scintigraphy in patients with differentiated thyroid cancer: no additional value of higher scan dose. Ann Nucl Med 2004; 18: 641-646.
50 Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80: 1488-1492.
51 Riemann B, Kramer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Sauerland C, Frankewitsch T, Schober O. Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin 2010; 49: 79-84.
52 Riemann B, Uhrhan K, Dietlein M, Schmidt D, Kuwert T, Dorn R, Sciuk J, Kodalle T, Schober O. Diagnostic value and therapeutic impact of 18F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study. Nuklearmedizin 2013; 52: 1-6.
53 Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?. J Clin Endocrinol Metab 2002; 87: 3242-3247.
54 Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy- D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91: 498-505.
55 Salvatori M, Rufini V, Reale F, Gajate AMS, Maussier ML, Revelli L, Troncone L, Ardito G. Radioguided surgery for lymph node recurrences of differentiated thyroid cancer. World Journal of Surgery 2003; 27: 770-775.
56 Schlumberger M, Berg G, Cohen O. et al. Followup of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004; 150: 105-112.
57 Schlumberger M, Catargi B, Borget I. et al. Strategies of radioiodine ablation in patients with lowrisk thyroid cancer. N Engl J Med 2012; 366: 1663-1673.
58 Siddiqi A, Foley RR, Britton KE, Sibtain A, Plowman PN, Grossman AB, Monson JP, Besser GM. The role of 123I-diagnostic imaging in the followup of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol (Oxf) 2001; 55: 515-521.
59 Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New-York: Wiley-Blackwell; 2009
60 Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 2011; 96: 3615-3627.
61 bStrahlenschutzkommission. Notwendigkeit der stationären Durchführung der Ganzkörperszintigraphie mit I-131 beim Schilddrüsenkarzinom. Empfehlung der Strahlenschutzkommission. Verabschiedet in der 190. Sitzung der SSK am 22./23. April 2004. Bundesanzeiger. 2004: 158.
62 bStrahlenschutzkommission. Qualitätskontrolle von nuklearmedizinischen Geräten – Festlegung von Reaktionsschwellen und Toleranzgrenzen. Verabschiedet in der 243. Sitzung der Strahlschutzkommission am 16./17. September 2010. 2010
63 Thies ED, Tanase K, Maeder U, Luster M, Buck AK, Hanscheid H, Reiners C, Verburg FA. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2014; 41: 2281-2290.
64 Torlontano M, Crocetti U, D’Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, Schlumberger M, Trischitta V. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 2003; 148: 19-24.
65 Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new american thyroid association staging system. Thyroid 2010; 20: 1341-1349.
66 Verburg FA, de Keizer B, Lips CJ, Zelissen PM, de Klerk JM. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 2005; 152: 33-37.
67 Verburg FA, Hanscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, Reiners C, Luster M. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 2010; 37: 896-903.
68 Verburg FA, Luster M, Cupini C, Chiovato L, Duntas LH, Elisei R, Feldt-Rasmussen U, Smit JW, Rimmele H, Seregni E, Theimer C, Giovanella L. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position paper. Thyroid. 2013
69 Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mader U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 276-283.
70 Verburg FA, Verkooijen RB, Stokkel MP, van Isselt JW. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin 2009; 48: 138-142.